Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for chronic weight management in adults. The therapy is recommended as an adjunct to a reduced-calorie diet and increased physical activity.
The generic semaglutide injection will be launched under the brand name Noveltreat after the expiry of the semaglutide patent in India. The product has been approved following a review of Phase III clinical trial data conducted in India.
Noveltreat will be available in five dose strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg administered once weekly. The injection will be provided via a prefilled pen, designed for convenient and accurate dosing.
GLP-1 receptor agonists such as semaglutide are increasingly recognized for their role in managing obesity and metabolic health, addressing the growing burden of obesity and diabetes in India. Noveltreat has been developed to meet global quality standards and is supported by robust Indian clinical evidence on safety and efficacy for weight management. Sun Pharma, as the country’s largest pharmaceutical company with a focus on cardiometabolic therapies, aims to improve access to generic semaglutide across India following patent expiry.
In December 2025, Sun Pharma had also received DCGI approval to manufacture and market semaglutide injection for adults with inadequately controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. This indication will be marketed under the brand name Sematrinity once the patent expires in India.
